TargImmune Therapeutics AG (Basel, Switzerland), a privately held Swiss-based biotechnology company focused on ...
Monte Rosa Therapeutics, a US-Swiss biotech company focused on discovering and developing precision medicines that degrade disease-causing proteins, reached...
Basel, Switzerland and Strasbourg, France, 15 June 2021 — Alentis Therapeutics, the Swiss biotech developing breakthrough treatments for fibrotic diseases, today announced that it has raised USD67 (CHF60) million in a Series B financing round.
The Technologiepark Basel and the Swiss Biotech Association invite you to a virtual talk about: ‘How to attract and retain best talents for Life Sciences startups’.
CARB-X funds BioVersys up to US$ 15.34 million to further develop pyrrolocytosines, a novel class of broad-spectrum antibiotics, targeting difficult to treat ESKAPE pathogens